In conclusion, we show that lovastatin blocks leukemia proliferation in part through activation of cholesterol biosynthesis and induction of the transcription factor KLF2, capable of suppression the MAPKinase pathway, likely through downregulation of FAM83A and DDIT4. The gene discussed is KLF2; the disease is leukemia.